Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 01/31/24
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute painCNBC • 01/30/24
Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says AnalystInvestors Business Daily • 01/30/24
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute PainBusiness Wire • 01/30/24
A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over FistThe Motley Fool • 01/22/24
Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar RangeSeeking Alpha • 01/22/24
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5Business Wire • 01/17/24
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex StockInvestors Business Daily • 01/16/24
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta ThalassemiaBusiness Wire • 01/16/24